ReviewThe Lancet. Oncology2018
Medication overuse in oncology: current trends and future implications for patients and society.
Review in The Lancet. Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Financial toxicity of cancer care in low- and middle-income countries: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- De-implementing low-value care in cancer care delivery: a systematic review.Implementation science : IS · 2022Pooled it
- Review
- Time to de-implementation of low-value cancer screening practices: a narrative review.BMJ quality & safety · 2025Review
- How appropriate is treating patients diagnosed with advanced esophageal cancer with anticancer drugs? A multicenter retrospective cohort Spanish study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Quality assurance standards and their use in the preparation of parenteral systemic anticancer therapy products in healthcare establishments: a scoping review.European journal of hospital pharmacy : science and practice · 2024Article
- Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.The Prostate · 2024Article
- Nanomaterial-based Electrochemical Sensors for Multiplex Medicinal Applications.Current topics in medicinal chemistry · 2024Review
- The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.PloS one · 2024Article
- The senescent mesothelial matrix accentuates colonization by ovarian cancer cells.Cellular and molecular life sciences : CMLS · 2023Article
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL.Frontiers in pharmacology · 2023Article
- Article
- Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms.JCO oncology practice · 2022Review
- The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: A difference-in-differences analysis in a large tertiary hospital in China.Frontiers in public health · 2022Article
- What Promotes Medical Overuse: Perspective on Evolutionary Game between Administration and Medical Institutions.Computational and mathematical methods in medicine · 2022Article
- Review
- Cutaneous melanoma: cost of illness under Brazilian health system perspectives.BMC health services research · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The high cost of cancer care worldwide is largely attributable to rising drugs prices. Despite their high costs and potential toxic effects, anticancer treatments could be subject to overuse, which is defined as the provision of medical services that are more likely to harm than to benefit a patient. We found 30 studies documenting medication overuse in cancer, which included 16 examples of supportive medication overuse and 17 examples of antineoplastic medication overuse in oncology. Few specific agents have been assessed, and no studies investigated overuse of the most toxic or expensive medications currently used in cancer treatment. Although financial, psychological, or physical harms of medication overuse in cancer could be substantial, there is little published evidence addressing these harms, so their magnitude is unclear. Further research is needed to better quantify medication overuse, understand its implications, and help protect patients and the health-care system from overuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.